Dare Bioscience vs Longeveron
Longeveron is the larger business, with $1.2m of revenue in fiscal 2025 against $1.0m for Dare Bioscience (1.2 times as much). Dare Bioscience grew faster (10429.4% against -49.9%). Dare Bioscience kept more of each dollar of sales as profit: a net margin of -1300.7% against -1893.6%. Dare Bioscience carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Dare BioscienceDARE, 2025 | LongeveronLGVN, 2025 |
|---|---|---|
| Revenue | $1.0m | $1.2m |
| Revenue growth | 10429.4% | -49.9% |
| Net income | −$13.4m | −$22.7m |
| Operating margin | -1315.5% | -1942.2% |
| Net margin | -1300.7% | -1893.6% |
| Return on equity | — | -164.7% |
| Free cash flow | −$10.3m | −$18.9m |
| Cash | $24.7m | $4.7m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 24 | 37 |
| Market value | $9.7m | $55.5m |
| Price vs our value range | — | — |
| Moat score | — | 19 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |